Product Name:5-bromo-2-nitropyridine

IUPAC Name:5-bromo-2-nitropyridine

CAS:39856-50-3
Molecular Formula:C5H3BrN2O2
Purity:95%+
Catalog Number:CM107933
Molecular Weight:203

Packing Unit Available Stock Price($) Quantity
CM107933-500g in stock ŤŮƈ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:39856-50-3
Molecular Formula:C5H3BrN2O2
Melting Point:-
Smiles Code:O=[N+](C1=NC=C(Br)C=C1)[O-]
Density:
Catalog Number:CM107933
Molecular Weight:203
Boiling Point:
MDL No:MFCD00160411
Storage:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Ribociclib
FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.

Related Products